Ovid Therapeutics Ownership | Who Owns Ovid Therapeutics?

Overview Forecast RevenueFinancials Chart

Ovid Therapeutics Ownership Summary

Ovid Therapeutics is owned by 8.55% institutional investors, 16.13% insiders, and 75.32% retail investors. Takeda pharmaceutical is the largest institutional shareholder, holding 10.59% of OVID shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.52% of its assets in Ovid Therapeutics shares.

OVID Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Ovid Therapeutics	8.55%	16.13%	75.32%
Sector	Healthcare Stocks	42.54%	10.83%	46.63%
Industry	Biotech Stocks	45.22%	10.75%	44.04%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Takeda pharmaceutical	7.53M	10.59%	$9.79M
Blackrock	3.99M	5.65%	$3.07M
Vanguard group	2.82M	3.97%	$3.67M
Affinity asset advisors	2.65M	3.73%	$3.44M
Artal group	2.50M	3.54%	$1.92M
Acadian asset management	2.29M	3.22%	$2.97M
Renaissance	2.02M	2.84%	$2.62M
Abel hall	32.35K	2.59%	$10.67K
Sio capital management	1.43M	2.01%	$1.86M
Driehaus capital management	1.40M	1.97%	$1.82M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Takeda pharmaceutical	7.53M	59.82%	$9.79M
Sio capital management	1.43M	0.47%	$1.86M
Affinity asset advisors	2.65M	0.30%	$3.44M
Velan capital investment management lp	160.00K	0.20%	$208.00K
Ikarian capital	1.10M	0.14%	$1.42M
Tls advisors	18.86K	0.08%	$26.00K
Diadema partners lp	187.74K	0.06%	$244.06K
Artal group	2.50M	0.05%	$1.92M
Persistent asset partners	46.04K	0.04%	$59.85K
Kennedy capital management	1.11M	0.03%	$1.44M

Top Buyers

Holder	Shares	% Assets	Change
Affinity asset advisors	2.65M	0.30%	1.98M
Ikarian capital	1.10M	0.14%	1.10M
Schonfeld strategic advisors	883.15K	0.01%	883.15K
Marshall wace, llp	783.65K	0.00%	618.93K
Walleye capital	596.72K	0.00%	596.72K

Top Sellers

Holder	Shares	% Assets	Change
Ecor1 capital	-	-	-6.12M
Bvf inc/il	-	-	-3.85M
Siren	-	-	-2.85M
Madison avenue partners, lp	-	-	-1.31M
Ubs oconnor	-	-	-943.42K

New Positions

Holder	Shares	% Assets	Change	Value
Ikarian capital	1.10M	0.14%	1.10M	$1.42M
Schonfeld strategic advisors	883.15K	0.01%	883.15K	$1.15M
Walleye capital	596.72K	0.00%	596.72K	$775.73K
Boothbay fund management	486.88K	0.01%	486.88K	$632.94K
Simplex trading	387.51K	0.00%	387.51K	$503.00K

Sold Out

Holder	Change
Newedge advisors	-4.00
True wealth design	-8.00
Ifp advisors	-8.00
Nelson, van denburg & campbell wealth management group	-10.00
Frazier financial advisors	-10.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2025	26	-62.86%	6,077,081	-83.10%	8	0.33%	13	-60.61%	8	-61.90%
Jun 30, 2025	69	-15.85%	35,963,757	-7.47%	2,877	297.56%	34	17.24%	21	-25.00%
Mar 31, 2025	83	-	46,400,658	-2.45%	37	0.83%	29	-21.62%	28	33.33%
Dec 31, 2024	28	-63.16%	10,144,389	-73.85%	14	0.48%	13	-69.05%	7	-53.33%
Sep 30, 2024	76	2.70%	38,794,655	0.78%	54	1.84%	42	16.67%	15	-40.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	1.79M	2.52%	-
Vanguard Total Stock Mkt Idx Inv	1.75M	2.47%	-38.35K
Kennedy Micro Cap	1.04M	1.46%	-64.12K
Fidelity Small Cap Index	578.63K	0.81%	-
Vanguard Institutional Extnd Mkt Idx Tr	563.03K	0.79%	-256.56K
State St Russell Sm/Mid Cp® Indx NL Cl C	525.80K	0.74%	-
State St Russell Sm/Mid Cp® Indx SL Cl I	525.80K	0.74%	-
MEDICAL BioHealth EUR Acc	503.85K	0.71%	-
Kennedy Micro Cap Opportunities	465.48K	0.65%	82.64K
iShares Biotechnology ETF	393.77K	0.55%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Feb 26, 2025	ALEXANDER MARGARET A.	President and COO	Sell	$2.96K
Feb 26, 2025	Rona Jeffrey A	CBFO	Sell	$2.19K
Jan 27, 2025	ALEXANDER MARGARET A.	President and COO	Buy	$4.97K
Mar 18, 2024	LEVIN JEREMY M	CEO	Buy	$50.36K
Sep 12, 2022	Tardio Jason	Chief Operating Officer	Sell	$37.29K

Insider Transactions Trends

Date	Buy	Sell
2025 Q4	-	-
2025 Q1	1	2
2024 Q4	-	-
2024 Q3	-	-
2024 Q1	1	-

OVID Ownership FAQ

Who Owns Ovid Therapeutics?

Ovid Therapeutics shareholders are primarily institutional investors at 8.55%, followed by 16.13% insiders and 75.32% retail investors. The average institutional ownership in Ovid Therapeutics's industry, Biotech Stocks , is 45.22%, which Ovid Therapeutics falls below.

Who owns the most shares of Ovid Therapeutics?

Ovid Therapeutics’s largest shareholders are Takeda pharmaceutical (7.53M shares, 10.59%), Blackrock (3.99M shares, 5.65%), and Vanguard group (2.82M shares, 3.97%). Together, they hold 20.20% of Ovid Therapeutics’s total shares outstanding.

Does Blackrock own Ovid Therapeutics?

Yes, BlackRock owns 5.65% of Ovid Therapeutics, totaling 3.99M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 3.07M$. In the last quarter, BlackRock decreased its holdings by -203K shares, a -4.84% change.

Who is Ovid Therapeutics’s biggest shareholder by percentage of total assets invested?

Takeda pharmaceutical is Ovid Therapeutics’s biggest shareholder by percentage of total assets invested, with 59.82% of its assets in 7.53M Ovid Therapeutics shares, valued at 9.79M$.

Who is the top mutual fund holder of Ovid Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Ovid Therapeutics shares, with 2.52% of its total shares outstanding invested in 1.79M Ovid Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools